Page 2 - Erick Rowinsky News Today

Intellectus Partners LLC lessened its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 0.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,563 shares of the biotechnology company’s stock after selling 50 shares during the quarter. Intellectus Partners LLC’s holdings in Biogen […]

Needham & Company LLC reaffirmed their buy rating on shares of Biogen (NASDAQ:BIIB – Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. The brokerage currently has a $294.00 target price on the biotechnology company’s stock. Other equities research analysts have also recently issued reports about the company. Canaccord Genuity […]

Biogen Inc. (NASDAQ:BIIB – Free Report) – Research analysts at Wedbush decreased their Q2 2024 earnings per share estimates for shares of Biogen in a report issued on Wednesday, April 24th. Wedbush analyst L. Chico now forecasts that the biotechnology company will post earnings per share of $3.43 for the quarter, down from their previous […]

Biogen Inc. (NASDAQ:BIIB – Free Report) – Equities researchers at Wedbush reduced their Q2 2024 earnings per share estimates for shares of Biogen in a note issued to investors on Wednesday, April 24th. Wedbush analyst L. Chico now anticipates that the biotechnology company will earn $3.43 per share for the quarter, down from their prior […]

Biogen Inc. (NASDAQ:BIIB – Free Report) – Equities research analysts at William Blair lifted their Q2 2024 earnings per share estimates for shares of Biogen in a research report issued on Thursday, April 25th. William Blair analyst M. Minter now anticipates that the biotechnology company will post earnings per share of $3.79 for the quarter, […]

Biogen (NASDAQ:BIIB – Get Free Report) posted its earnings results on Wednesday. The biotechnology company reported $3.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.45 by $0.22, Briefing.com reports. Biogen had a net margin of 12.07% and a return on equity of 14.83%. The company had revenue of $2.29 billion […]

Biogen Inc. (NASDAQ:BIIB – Get Free Report) shares saw strong trading volume on Wednesday following a better than expected earnings announcement. 904,201 shares traded hands during mid-day trading, a decline of 22% from the previous session’s volume of 1,159,178 shares.The stock last traded at $204.63 and had previously closed at $193.18. The biotechnology company reported […]

Biogen (NASDAQ:BIIB – Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 15.000-16.000 for the period, compared to the consensus estimate of 15.460. The company issued revenue guidance of -. Biogen also updated its FY24 guidance to $15.00-16.00 EPS. Biogen […]

Biogen (NASDAQ:BIIB – Get Free Report) issued its quarterly earnings results on Wednesday. The biotechnology company reported $3.67 earnings per share for the quarter, topping analysts’ consensus estimates of $3.45 by $0.22, Briefing.com reports. Biogen had a return on equity of 14.83% and a net margin of 12.07%. The firm had revenue of $2.29 billion […]

Biogen (NASDAQ:BIIB – Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 15.000-16.000 for the period, compared to the consensus estimate of 15.460. The company issued revenue guidance of -. Biogen also updated its FY24 guidance to $15.00-16.00 EPS. Wall […]